Pancreatic carcinoma
Not yet recruitingPhase 2/3 study of telisotuzumab adizutecan with drug combination versus standard care in adults with first‑line metastatic pancreatic ductal adenocarcinoma
Phase 2/3 study of telisotuzumab adizutecan with drug combination versus standard care in adults with first‑line metastatic pancreatic ductal adenocarcinoma
- Disease:Pancreatic carcinoma
- Substances:Calcium FolinateFluorouracil+2
Austria- Participants:18–64 years · 65+ years
- Substances:Calcium Folinate
- Sponsor:AbbVie Deutschland GmbH & Co. KG














